.jpg)
Recent advances in ADC development have led to increasing diversity in antibody, linker and payload design. Successful drug product (DP) development for different ADCs in a CDMO environment requires a clear understanding of how key DP factors—including formulation, stability, manufacturing, dosage form, and route of administration— interact with one another and are influenced by ADC molecular design.
This presentation examines common challenges in ADC DPdevelopment and production from both theoretical and practical perspectives.Case studies will be shared to demonstrate practical solutions enabled by ourplatform technologies.
Key Learning Objectives
· Common challenges in ADC drug productdevelopment
· Strategies to mitigate light- andoxidation-induced degradation of ADCs
· Optimization of lyophilized DP formulations forADCs
· Customized in-use evaluations to supportclinical administration
Featuring Insights from
Shujing Wang
,
PhD
Dr. Wang joined AsymBio in 2022 and currently leads the DrugProduct Development team. Her responsibilities span formulation developability,drug product formulation and process development, technology transfer, and drugproduct process characterization across diverse biopharmaceutical modalities,including bioconjugates. Her team has supported drug product development for over150 projects across pre-IND, IND, late-stage clinical, and BLA stages. Dr. Wanggraduated from the National University of Singapore, specializing in structuralbiology and NMR. She has more than 14 years of experience in biopharmaceuticaldrug product development and previously worked at WuXi Biologics and Johnson& Johnson.
Sponsored by
.png)
